Reports

Global Anti-Fibrinolytic Drugs Market to Grow at a CAGR of 5% During 2021-2026, Aided by the Increasing Investments in R&D and Health Care

Anti-Fibrinolytic Drugs Market

Global Anti-Fibrinolytic Drugs Market: By Form: Oral, Injectable; By Type: Amicor, Aminocaproic acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Tranexamic Acid, Trasylol, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2018-2028); Competitive Landscape; Industry Events and Developments

Global Anti-Fibrinolytic Drugs Market Outlook

The global anti-fibrinolytic drugs market witnessed a healthy growth in the historical period of 2018-2022 aided by the rising healthcare sector in the emerging regions. The market is further expected to grow at a CAGR of 5% in the forecast period of 2023-2028.

 

North America to be a Significant Anti-Fibrinolytic Drugs Market

North America has been a significant market for anti-fibrinolytic drugs in the past years and is expected to continue the trend. This dominance of the region can be attributed to the rising numbers of severe road accidents and trauma. A significant proportion of the deaths in North America are reported to be caused by trauma. The rising incidences of platelet dysfunctions, Von Willebrand disease, haemophilia A and B, which require anti-fibrinolytic drugs to inhibit fibrinolysis, are expected to contribute to the growth of the anti-fibrinolytic drugs industry in North America. Europe, the Asia Pacific, and Latin America are the other significant markets for the drugs, apart from North America. The growing investments in healthcare R&D are expected to augment the anti-fibrinolytic drugs industry growth globally in the forecast period.

 

Anti-Fibrinolytic Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Anti-Fibrinolytic Drugs: Market Segmentation

Fibrinolysis is a natural physiological process that prevents blood clotting. It is carried out by converting plasminogen to plasmin. It can cause persistent bleeding and trauma, which might ultimately lead to death. Anti-fibrinolytic drugs like aminocaproic acid and tranexamic acid are lysine-like agents that prevent plasmin (fibrinolytic enzyme) formation by hindering the binding sites of the enzyme at lysin-rich areas, thus, inhibiting fibrinolysis. These drugs are used in the treatment of various coagulation disorders and medical surgeries.

By form, the market can be segmented into:

  • Oral 
  • Injectable

Based on type, the market can be classified into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.
 
Based on indication, the market is segmented into:

  • Gynaecology
  • Hereditary Angioedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others

Based on end-use, the market can be categorised into:

  • Hospitals
  • Ambulatory Surgery Centres
  • Health Care Speciality Processes
  • Clinics

The EMR report looks into the regional markets of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

 

Rise in Road Accidents to Drive the Anti-Fibrinolytic Drugs Market Growth

The market is being driven by a significant rise in road accidents, which cause severe bleeding. Trauma is observed to be one of the significant mortality causes across the world, hence, increasing the demand for anti-fibrinolytic drugs. Further, the usage of the drugs in oral bleeding treatments is bolstering the market growth further. The rising adoption of these drugs for the treatment of menorrhagia, i.e., heavy menstrual flow, is expected to bolster the anti-fibrinolytic drugs industry in the coming years. The increasing investments in the R&D of hemophilia products are also predicted to influence the demand for the drugs in the forecast period.
 

Key Industry Players in the Global Anti-Fibrinolytic Drugs Market

The report presents a detailed analysis of the following key players in the global anti-fibrinolytic drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Pfizer Inc.
  • Sanofi SA
  • Akorn, Inc
  • Cadila Healthcare Ltd.
  • Takeda Pharmaceutical Company Limited
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Form, Type, Indication, End Use, Region
Breakup by Form Oral, Injectable
Breakup by Type Amicor, Aminocaproic acid, Aprotinin, Lysteda, RiaSTAP, Fibrinogen, Tranexamic Acid, Trasylol, Others
Breakup by Indication Gynaecology, Hereditary Angioedema, Fibrinolytic Response Testing, Surgeries, Others
Breakup by End Use Hospitals, Ambulatory Surgery Centres, Health Care Specialty Processes, Clinics
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Pfizer Inc., Sanofi SA, Akorn, Inc., Cadila Healthcare Ltd., Takeda Pharmaceutical Company Limited, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description
    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary
    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Anti-Fibrinolytic Drugs Market Analysis
    8.1    Key Industry Highlights
    8.2    Global Anti-Fibrinolytic Drugs Historical Market (2018-2022) 
    8.3    Global Anti-Fibrinolytic Drugs Market Forecast (2023-2028)
    8.4    Global Anti-Fibrinolytic Drugs Market by Form
        8.4.1    Oral
            8.4.1.1    Historical Trend (2018-2022)
            8.4.1.2    Forecast Trend (2023-2028)
        8.4.2    Injectable
            8.4.2.1    Historical Trend (2018-2022)
            8.4.2.2    Forecast Trend (2023-2028)
    8.5    Global Anti-Fibrinolytic Drugs Market by Type
        8.5.1    Amicor
            8.5.1.1    Historical Trend (2018-2022)
            8.5.1.2    Forecast Trend (2023-2028)
        8.5.2    Aminocaproic acid
            8.5.2.1    Historical Trend (2018-2022)
            8.5.2.2    Forecast Trend (2023-2028)
        8.5.3    Aprotinin
            8.5.3.1    Historical Trend (2018-2022)
            8.5.3.2    Forecast Trend (2023-2028)
        8.5.4    Lysteda
            8.5.4.1    Historical Trend (2018-2022)
            8.5.4.2    Forecast Trend (2023-2028)
        8.5.5    RiaSTAP
            8.5.5.1    Historical Trend (2018-2022)
            8.5.5.2    Forecast Trend (2023-2028)
        8.5.6    Fibrinogen
            8.5.6.1    Historical Trend (2018-2022)
            8.5.6.2    Forecast Trend (2023-2028)
        8.5.7    Tranexamic Acid
            8.5.7.1    Historical Trend (2018-2022)
            8.5.7.2    Forecast Trend (2023-2028)
        8.5.8    Trasylol
            8.5.8.1    Historical Trend (2018-2022)
            8.5.8.2    Forecast Trend (2023-2028)
        8.5.9    Others
    8.6    Global Anti-Fibrinolytic Drugs Market by Indication
        8.6.1    Gynaecology
            8.6.1.1    Historical Trend (2018-2022)
            8.6.1.2    Forecast Trend (2023-2028)
        8.6.2    Hereditary Angioedema
            8.6.2.1    Historical Trend (2018-2022)
            8.6.2.2    Forecast Trend (2023-2028)
        8.6.3    Fibrinolytic Response Testing
            8.6.3.1    Historical Trend (2018-2022)
            8.6.3.2    Forecast Trend (2023-2028)
        8.6.4    Surgeries
            8.6.4.1    Historical Trend (2018-2022)
            8.6.4.2    Forecast Trend (2023-2028)
        8.6.5    Others
    8.7    Global Anti-Fibrinolytic Drugs Market by End Use
        8.7.1    Hospitals
            8.7.1.1    Historical Trend (2018-2022)
            8.7.1.2    Forecast Trend (2023-2028)
        8.7.2    Ambulatory Surgery Centres
            8.7.2.1    Historical Trend (2018-2022)
            8.7.2.2    Forecast Trend (2023-2028)
        8.7.3    Health Care Specialty Processes
            8.7.3.1    Historical Trend (2018-2022)
            8.7.3.2    Forecast Trend (2023-2028)
        8.7.4    Clinics
            8.7.4.1    Historical Trend (2018-2022)
            8.7.4.2    Forecast Trend (2023-2028)
    8.8    Global Anti-Fibrinolytic Drugs Market by Region       
        8.8.1    North America
            8.8.1.1    Historical Trend (2018-2022) 
            8.8.1.2    Forecast Trend (2023-2028)
        8.8.2    Europe
            8.8.2.1    Historical Trend (2018-2022) 
            8.8.2.2    Forecast Trend (2023-2028)
        8.8.3    Asia Pacific
            8.8.3.1    Historical Trend (2018-2022) 
            8.8.3.2    Forecast Trend (2023-2028)
        8.8.4    Latin America
            8.8.4.1    Historical Trend (2018-2022) 
            8.8.4.2    Forecast Trend (2023-2028)
        8.8.5    Middle East and Africa
            8.8.5.1    Historical Trend (2018-2022) 
            8.8.5.2    Forecast Trend (2023-2028) 
9    North America Anti-Fibrinolytic Drugs Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2022) 
        9.1.2    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Historical Trend (2018-2022) 
        9.2.2    Forecast Trend (2023-2028)
10    Europe Anti-Fibrinolytic Drugs Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2022) 
        10.1.2    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Historical Trend (2018-2022) 
        10.2.2    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Historical Trend (2018-2022) 
        10.3.2    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Historical Trend (2018-2022) 
        10.4.2    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Anti-Fibrinolytic Drugs Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2022) 
        11.1.2    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Historical Trend (2018-2022) 
        11.2.2    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Historical Trend (2018-2022) 
        11.3.2    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2022) 
        11.4.2    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Historical Trend (2018-2022) 
        11.5.2    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Anti-Fibrinolytic Drugs Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2022) 
        12.1.2    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2022) 
        12.2.2    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2022) 
        12.3.2    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Anti-Fibrinolytic Drugs Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2022) 
        13.1.2    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2022) 
        13.2.2    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2022) 
        13.3.2    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2022) 
        13.4.2    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape
    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Pfizer Inc.
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Sanofi SA
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Akorn, Inc.
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Cadila Healthcare Ltd.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Takeda Pharmaceutical Company Limited
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Anti-Fibrinolytic Drugs Market: Key Industry Highlights, 2018 and 2028
2.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Form (USD Billion), 2018-2022
3.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Form (USD Billion), 2023-2028
4.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Type (USD Billion), 2018-2022
5.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Type (USD Billion), 2023-2028
6.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Indication (USD Billion), 2018-2022
7.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Indication (USD Billion), 2023-2028
8.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by End Use (USD Billion), 2018-2022
9.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by End Use (USD Billion), 2023-2028
10.    Global Anti-Fibrinolytic Drugs Historical Market: Breakup by Region (USD Billion), 2018-2022
11.    Global Anti-Fibrinolytic Drugs Market Forecast: Breakup by Region (USD Billion), 2023-2028
12.    North America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
13.    North America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
14.    Europe Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
15.    Europe Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
16.    Asia Pacific Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
17.    Asia Pacific Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
18.    Latin America Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
19.    Latin America Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
20.    Middle East and Africa Anti-Fibrinolytic Drugs Historical Market: Breakup by Country (USD Billion), 2018-2022
21.    Middle East and Africa Anti-Fibrinolytic Drugs Market Forecast: Breakup by Country (USD Billion), 2023-2028
22.    Global Anti-Fibrinolytic Drugs Market Structure

Key Questions Answered in the Report

What is the growth rate of the market?

The market is projected to grow at a CAGR of 5% between 2023 and 2028.

What are the major market drivers?

The major market drivers include the rising frequency of road accidents, increasing usage of the product in oral bleeding treatments, and the rising R&D investments in hemophilia products.

What are the key industry trends of the global anti-fibrinolytic drugs market?

The key trends steering the market include the growing adoption of the drugs in the treatment of menorrhagia.

What are the major regional markets of anti-fibrinolytic drugs, according to the EMR report?

The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

What are the major types of the drugs in the market?

The major types of the drugs in the market are amicor, aminocaproic acid, aprotinin, lysteda, RiaSTAP, fibrinogen, tranexamic acid, and trasylol, among others.

What are the leading forms of the product in the industry?

Oral and injectable are the leading forms of the product in the industry.

What are the major indication segments within the market?

The major indication segments within the market are gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others.

What are the significant end-use sectors within the market?

The significant end use sectors within the market are hospitals, ambulatory centres, health care specialty processes, and clinics.

Who are the key industry players, according to the report?

Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company Limited, among others, are the key industry players.

Analyst Review

The global anti-fibrinolytic drugs market is driven by the rising demand for the product in hemophilia treatments. Aided by the increasing investments in R&D, the market is expected to witness a healthy growth in the forecast period of 2023-2028, growing at a CAGR of 5%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. On the basis of form, the industry can be bifurcated into oral and injectable. Based on its types, the market can be segmented into amicor, aminocaproic acid, aprotinin, lysteda, riaSTAP, fibrinogen, tranexamic acid, and trasylol, among others. On the basis of indication, the market is divided into gynaecology, hereditary angioedema, fibrinolytic response testing, and surgeries, among others. By end use, the market is categorised into hospitals, ambulatory centres, health care specialty processes, and clinics. The major regional markets for the anti-fibrinolytic drugs are North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, Akorn, Inc, Cadila Healthcare Ltd., and Takeda Pharmaceutical Company, among others.

LimitedEMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Single User License

$2799
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now
most popular

Five User License

$3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Corporate License

$4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER